Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acrivon Therapeutics, Inc. - Common Stock
(NQ:
ACRV
)
6.420
-0.020 (-0.31%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Acrivon Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
November 13, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
October 17, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
October 11, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
September 14, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
September 10, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
September 09, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 13, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
April 24, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
April 16, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
April 10, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces $130 Million Private Placement Financing
April 09, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 28, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
March 05, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
March 04, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
February 08, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
January 03, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
November 28, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
November 21, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 09, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 16, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 28, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on
September 19, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.